NCT04834674 2026-04-07
DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma
Sichuan Cancer Hospital and Research Institute
Phase 2 Completed
Clinical Trials
10 trialsNCT06925516 2025-11-28
ACADEMY
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT06296563 2024-04-17
Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT04454905 2023-04-19
Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study
Sun Yat-sen University
Phase 2 Unknown
NCT05400902 2023-04-13
HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT05653817 2022-12-16
Advanced or Metastatic Cholangiocarcinoma
First Affiliated Hospital Xi'an Jiaotong University
Phase NA Unknown
NCT05290116 2022-08-05
HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT04642664 2021-06-03
ACABC
Peking Union Medical College Hospital
Phase 2 Completed
NCT03251443 2020-12-02
A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
Peking Union Medical College Hospital
Phase 2 Completed
NCT03521219 2018-05-11
A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown